The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later

Veterinary Research

Volumn 45, Issue 1, 2014, Pages

  Martin, Virginie ^a   Vouldoukis, Ioannis ^b   Moreno, Javier ^c   McGahie, David ^a   Gueguen, Sylvie ^a   Cuisinier, Anne Marie ^a  

^a Virbac SA   (France)

^b INSERM   (France)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS; LEISHMANIA INFANTUM;

LEISHMANIA VACCINE;

ADAPTIVE IMMUNITY; ANIMAL; ANIMAL DISEASE; ARTICLE; BONE MARROW; DOG; DOG DISEASE; FEMALE; IMMUNIZATION; IMMUNOLOGY; LEISHMANIA INFANTUM; MALE; PARASITE LOAD; PARASITOLOGY; TH1 CELL; TIME; VISCERAL LEISHMANIASIS;

ADAPTIVE IMMUNITY; ANIMALS; BONE MARROW; DOG DISEASES; DOGS; FEMALE; IMMUNIZATION SCHEDULE; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; PARASITE LOAD; TH1 CELLS; TIME FACTORS;

EID: 84902945629     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-45-69     Document Type: Article

References (69)

1. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Solano-Gallego L, Koutinas A, Miró G, Cardoso L, Pennisi MG, Ferrer L, Bourdeau P, Oliva G, Baneth G, Vet Parasitol 2009 165 1 18
2. The biology and control of Phlebotomine sand flies. Killick-Kendrick R, Clin Dermatol 1999 17 279 289 (Pubitemid 29497892)
3. Deltamethrin-impregnated collars for the control of canine leishmaniasis: evaluation of the protective effect and influence on the clinical outcome of Leishmania infection in kennelled stray dogs. Foglia Manzillo V, Oliva G, Pagano A, Manna L, Maroli M, Gradoni L, Vet Parasitol 2006 142 142 145 (Pubitemid 44584542)
4. Prospective study on the incidence and progression of clinical signs in naïve dogs naturally infected by Leishmania infantum. Foglia Manzillo V, Di Muccio T, Cappiello S, Scalone A, Paparcone R, Fiorentino E, Gizzarelli M, Gramiccia M, Gradoni L, Oliva G, PLoS Negl Trop Dis 2013 7 2225
5. Risk factors for canine leishmaniasis in an endemic Mediterranean region. Cortes S, Vaz Y, Neves R, Maia C, Cardoso L, Campino L, Vet Parasitol 2012 189 189 196
6. Transplacental transmission of a North American isolate of Leishmania infantum in an experimentally infected beagle. Rosypal AC, Troy GC, Zajac AM, Frank G, Lindsay DS, J Parasitol 2005 91 970 972 (Pubitemid 41324791)
7. Venereal transmission of canine visceral leishmaniasis. Silva FL, Oliveira RG, Silva TMA, Xavier MN, Nascimento EF, Santos RL, Vet Parasitol 2009 160 55 59
8. Transmission of Leishmania infantum via blood transfusion in dogs: potential for infection and importance of clinical factors. De Freitas E, Melo MN, da Costa-Val AP, Michalick MSM, Vet Parasitol 2006 137 159 167 (Pubitemid 43384039)
9. Canine leishmaniasis. Alvar J, Cañavate C, Molina R, Moreno J, Nieto J, Adv Parasitol 2004 57 1 88 (Pubitemid 39422432)
10. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. Solano-Gallego L, Morell P, Arboix M, Alberola J, Ferrer L, J Clin Microbiol 2001 39 560 563 (Pubitemid 32150817)
11. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romão P, Silveira H, Vet Immunol Immunopathol 2002 88 21 30 (Pubitemid 34667160)
12. Cytokine profiles in canine visceral leishmaniasis. Carrillo E, Moreno J, Vet Immunol Immunopathol 2009 128 67 70
13. Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs-a preliminary xenodiagnosis study. Bongiorno G, Paparcone R, Foglia Manzillo V, Oliva G, Cuisinier A-M, Gradoni L, Vet Parasitol 2013 197 691 695
14. The logic of visceral leishmaniasis control. Dye C, Am J Trop Med Hyg 1996 55 125 130 (Pubitemid 26299194)
15. Recent advances in leishmaniosis in pet animals: epidemiology, diagnostics and anti-vectorial prophylaxis. Gramiccia M, Vet Parasitol 2011 181 23 30
16. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, Luz KG, Palatnik M, Palatnik de Sousa CB, Vaccine 2002 20 3277 3284 (Pubitemid 35251815)
17. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Fernandes AP, Costa MMS, Coelho EAF, Michalick MSM, de Freitas E, Melo MN, Luiz Tafuri W, Resende DDM, Hermont V, Abrantes CDF, Gazzinelli RT, Vaccine 2008 26 5888 5895
18. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Fernandes AP, Coelho EAF, Machado-Coelho GLL, Grimaldi G, Gazzinelli RT, Curr Opin Microbiol 2012 15 476 485
19. Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs. Moreno J, Vouldoukis I, Martin V, McGahie D, Cuisinier A-M, Gueguen S, PLoS Negl Trop Dis 2012 6 1683
20. Primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) produces a cell-mediated immune response which is still present 1 year later. Moreno J, Vouldoukis I, Schreiber P, Martin V, McGahie D, Gueguen S, Cuisinier A-M, Vet Immunol Immunopathol 2014 158 1 9
21. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. Murray HW, Hariprashad J, Coffman RL, J Exp Med 1997 185 867 874 (Pubitemid 27119870)
22. Patent application No FR2705358A1: Procédé de culture in vitro de différents stades de parasites tissulaires obtenus et applications biologiques. Lemesre JL, 1993
23. New insights into the developmental biology and transmission mechanisms of Leishmania. Bates PA, Rogers ME, Curr Mol Med 2004 4 601 609 (Pubitemid 39172366)
24. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. Mary C, Faraut F, Lascombe L, Dumon H, J Clin Microbiol 2004 42 5249 5255 (Pubitemid 39506237)
25. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Moreno J, Nieto J, Chamizo C, González F, Blanco F, Barker DC, Alvar J, Vet Immunol Immunopathol 1999 71 181 195 (Pubitemid 29528238)
26. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Carrillo E, Crusat M, Nieto J, Chicharro C, Thomas Mdel C, Martínez E, Valladares B, Cañavate C, Requena JM, López MC, Alvar J, Moreno J, Vaccine 2008 26 1902 1911
27. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Holzmuller P, Cavaleyra M, Moreaux J, Kovacic R, Vincendeau P, Papierok G, Lemesre J-L, Vet Immunol Immunopathol 2005 106 247 257 (Pubitemid 40814374)
28. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Neogy AB, Vouldoukis L, Da Costa JM, Monjour L, Vet Parasitol 1994 54 367 373 (Pubitemid 24329905)
29. Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Vouldoukis I, Drapier JC, Nüssler AK, Tselentis Y, Da Silva OA, Gentilini M, Mossalayi DM, Monjour L, Dugas B, Antimicrob Agents Chemother 1996 40 253 256 (Pubitemid 26019708)
30. Canine visceral leishmaniasis: Comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vouldoukis I, Rougier S, Dugas B, Pino P, Mazier D, Woehrlé F, Vet Parasitol 2006 135 137 146 (Pubitemid 43003540)
31. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Tietze F, Anal Biochem 1969 27 502 522
32. Identification and quantitation of glutathione in hepatic protein mixed disulfides and its relationship to glutathione disulfide. Brigelius R, Muckel C, Akerboom TPM, Sies H, Biochem Pharmacol 1983 32 2529 2534 (Pubitemid 13006940)
33. The true oxidized glutathione content of red blood cells obtained by new enzymic and paper chromatographic methods. Güntherberg H, Rost J, Anal Biochem 1966 15 205 210
34. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, Scalone A, Di Muccio T, Oliva G, Vaccine 2005 23 5245 5251 (Pubitemid 41443430)
35. Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. Paltrinieri S, Solano-Gallego L, Fondati A, Lubas G, Gradoni L, Castagnaro M, Crotti A, Maroli M, Oliva G, Roura X, Zatelli A, Zini E, J Am Vet Med Assoc 2010 236 1184 1191
36. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Carvalho MG, Mayrink W, França-Silva JC, Giunchetti RC, Genaro O, Corrêa-Oliveira R, Res Vet Sci 2006 81 68 75 (Pubitemid 43323779)
37. Canine leishmaniasis: epidemiological risk and the experimental model. Moreno J, Alvar J, Trends Parasitol 2002 18 399 405
38. Experimental model for reproduction of canine visceral leishmaniosis by Leishmania infantum. Fernández-Cotrina J, Iniesta V, Belinchón- Lorenzo S, Muñoz-Madrid R, Serrano F, Parejo JC, Gómez-Gordo L, Soto M, Alonso C, Gómez-Nieto LC, Vet Parasitol 2013 192 118 128
39. Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs. Poot J, Rogers ME, Bates PA, Vermeulen A, Vet Parasitol 2005 130 41 53 (Pubitemid 40694136)
40. Animal models for vaccine studies for visceral leishmaniasis. Garg R, Dube A, Indian J Med Res 2006 123 439 454 (Pubitemid 43905581)
41. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Lemesre J-L, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G, Vaccine 2005 23 2825 2840 (Pubitemid 40386484)
42. Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs. Bourdoiseau G, Hugnet C, Gonçalves RB, Vézilier F, Petit-Didier E, Papierok G, Lemesre JL, Vet Immunol Immunopathol 2009 128 71 78
43. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mayrink W, Genaro O, Silva JC, da Costa RT, Tafuri WL, Toledo VP, da Silva AR, Reis AB, Williams P, da Costa PW, Mem Inst Oswaldo Cruz 1996 91 695 697
44. Phase III randomized double blind clinical trial of the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil [abstract]. Genaro O, Pinto JA, Da Costa CA, França-Silva JC, Costa RT, Silva JC, Sanguinetti LSR, Vieira EP, Toledo VPCP, Mayrink W, Mem Inst Oswaldo Cruz 1996 91 166
45. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA, Vaccine 2005 23 3716 3725 (Pubitemid 40692418)
46. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J, Vaccine 2007 25 7962 7971 (Pubitemid 47632977)
47. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Moreno J, Nieto J, Masina S, Cañavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J, Vaccine 2007 25 5290 5300 (Pubitemid 46977538)
48. Experimental canine leishmaniasis: clinical, parasitological and serological follow-up. Maia C, Nunes M, Cristóvão J, Campino L, Acta Trop 2010 116 193 199
49. Immune response regulation by leishmania secreted and nonsecreted antigens. Santarém N, Silvestre R, Tavares J, Silva M, Cabral S, Maciel J, Cordeiro-da-Silva A, J Biomed Biotechnol 2007 2007 85154
50. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Reis AB, Giunchetti RC, Carrillo E, Martins-Filho OA, Moreno J, Trends Parasitol 2010 26 341 349
51. La leishmaniose canine à Leishmania infantum: essais d'immunothérapie. Bourdoiseau G, Hugnet C, Papierok G-M, Lemesre JL, Bull Acad Vet Fr 2004 157 63 67
52. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G, Vaccine 2007 25 4223 4234 (Pubitemid 46661824)
53. Clinical and laboratory monitoring of dogs naturally infected by Leishmania infantum. Paradies P, Sasanelli M, de Caprariis D, Testini G, Traversa D, Lia RP, Dantas-Torres F, Otranto D, Vet J 2010 186 370 373
54. Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons. Oliva G, Scalone A, Foglia Manzillo V, Gramiccia M, Pagano A, Di Muccio T, Gradoni L, J Clin Microbiol 2006 44 1318 1322
55. Immunologic indicators of clinical progression during canine Leishmania infantum infection. Boggiatto PM, Ramer-Tait AE, Metz K, Kramer EE, Gibson-Corley K, Mullin K, Hostetter JM, Gallup JM, Jones DE, Petersen CA, Clin Vaccine Immunol 2010 17 267 273
56. Early suppression of lymphoproliferative response in dogs with natural infection by Leishmania infantum. De Luna R, Vuotto ML, Ielpo MT, Ambrosio R, Piantedosi D, Moscatiello V, Ciaramella P, Scalone A, Gradoni L, Mancino D, Vet Immunol Immunopathol 1999 70 95 103 (Pubitemid 29428047)
57. Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi. Alves CF, de Amorim IFG, Moura EP, Ribeiro RR, Alves CF, Michalick MS, Kalapothakis E, Bruna-Romero O, Tafuri WL, Teixeira MM, Melo MN, Vet Immunol Immunopathol 2009 128 349 358
58. Clinical, parasitologic, and immunologic evolution in dogs experimentally infected with sand fly-derived Leishmania chagasi promastigotes. Travi BL, Osorio EY, Saldarriaga OA, Cadena H, Tabares CJ, Peniche A, Lee S, Melby PC, Am J Trop Med Hyg 2009 81 994 1003
59. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Vouldoukis I, Bécherel PA, Riveros-Moreno V, Arock M, da Silva O, Debré P, Mazier D, Mossalayi MD, Eur J Immunol 1997 27 860 865 (Pubitemid 27153653)
60. Canine visceral leishmaniasis in Colombia: relationship between clinical and parasitologic status and infectivity for sand flies. Travi BL, Tabares CJ, Cadena H, Ferro C, Osorio Y, Am J Trop Med Hyg 2001 64 119 124 (Pubitemid 32565839)
61. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C, J Infect Dis 2002 186 1314 1320 (Pubitemid 35193010)
62. Superoxide dismutase and Glutathione peroxidase in the blood of dogs with Leishmaniasis. Britti D, Sconza S, Morittu VM, Santori D, Boari A, Vet Res Commun 2008 32 Suppl 1 251 S254
63. Canine visceral leishmaniasis: relationships between oxidative stress, liver and kidney variables, trace elements, and clinical status. Heidarpour M, Soltani S, Mohri M, Khoshnegah J, Parasitol Res 2012 111 1491 1496
64. Leishmania-macrophage interactions: insights into the redox biology. Van Assche T, Deschacht M, da Luz RA, Maes L, Cos P, Free Radic Biol Med 2011 51 337 351
65. Redox regulation of cellular activation. Nakamura H, Nakamura K, Yodoi J, Annu Rev Immunol 1997 15 351 369 (Pubitemid 27169285)
66. Differential effects of glutathione depletion on T cell subsets. Gmünder H, Dröge W, Cell Immunol 1991 138 229 237
67. Role of glutathione in macrophage activation: effect of cellular glutathione depletion on nitrite production and leishmanicidal activity. Buchmüller-Rouiller Y, Corrandin SB, Smith J, Schneider P, Ransijn A, Jongeneel CV, Mauël J, Cell Immunol 1995 164 73 80
68. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Murata Y, Shimamura T, Hamuro J, Int Immunol 2002 14 201 212 (Pubitemid 34144744)
69. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C, Proc Natl Acad Sci U S A 1998 95 3071 3076 (Pubitemid 28135856)